Market research
LUPIN.NSE Lupin Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1T
- P/E ratio
- 18.13
- Analyst target
- 2513.2222
- Dividend yield
- 0.0%
- Beta
- 0.18
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE326A01037
- Market cap
- 1T
- P/E ratio
- 18.13
- Analyst target
- 2513.2222
- Dividend yield
- 0.0%
- Beta
- 0.18
About
About Lupin Limited
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies. In addition, it provides chronic therapies, and hospital-based products; products for diabetes and iron supplements for anemia, and a Budesonide-Formoterol combination for asthma. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consisting of labs and collection centers. The company has a strategic collaboration with TB Alliance to support the clinical development and commercialization of Telacebec for the treatment of tuberculosis, leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the LUPIN.NSE discussion.
5 years, 5 months ago
Lupin Limited is currently in a long term uptrend where the price is trading 9.5% above its 200 day moving average.
From a valuation standpoint, the stock is 35.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.1.
Lupin Limited's total revenue rose by 3.9% to $39B since the same quarter in the previous year.
Its net income has increased by 152.5% to $4B since the same quarter in the previous year.
Finally, its free cash flow fell by 77.5% to $4B since the same quarter in the previous year.
Based on the above factors, Lupin Limited gets an overall score of 4/5.